Download MMP Preferred Drugs - SSRs and SNRIs

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
MMP Preferred Drugs - SSRIs and SNRIs
As part of the Preferred Drugs initiative the Medicines Management
Programme (MMP) is considering two further drug classes;
 selective serotonin re-uptake inhibitors (SSRIs)
 serotonin noradrenaline re-uptake inhibitors (SNRIs)
These drug classes are being reviewed with the aim of recommending the
preferred SSRI and SNRI to prescribers in the first quarter of 2014.
The SSRIs being considered for inclusion in the Preferred Drugs initiative are:
 citalopram,
 escitalopram,
 fluoxetine,
 fluvoxamine,
 paroxetine
 sertraline.
These drugs are used for a wide range of conditions including depression,
generalised anxiety disorder, panic disorder, etc.
The SNRIs for consideration are:
 venlafaxine
 duloxetine.
The MMP now invite submissions from stakeholders to inform the selection
process which will consider a range of criteria including licensed therapeutic
indication(s), clinical outcome data, clinical guidelines, cost, patient factors
and prescribing trends in Ireland.
Submissions should be made to:
The National Centre for Pharmacoeconomics, St. James’s Hospital, Dublin 8
or info@ncpe.ie
The closing date for submissions is close of business on Wednesday 30th
November, 2013.